|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Yang W and Guan L: Bridging the US and
China together to conquer cancer: report of the 4th annual meeting
of the US Chinese Anti-Cancer Association (USCACA). Chin J Cancer.
31:315–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang L, Parkin DM, Ferlay J, Li L and Chen
Y: Estimates of cancer incidence in China for 2000 and projections
for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250.
2005.PubMed/NCBI
|
|
4
|
Zheng S, Bai JQ, Li J, et al: The
pathologic characteristics of breast cancer in China and its shift
during 1999–2008: A national-wide multicenter cross-sectional image
over 10 years. Int J Cancer. 131:2622–2631. 2012.PubMed/NCBI
|
|
5
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009.PubMed/NCBI
|
|
7
|
Lopez F, Belloc F, Lacombe F, et al:
Modalities of synthesis of Ki67 antigen during the stimulation of
lymphocytes. Cytometry. 12:42–49. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldhirsch A, Wood WC, Coates AS, et al:
Strategies for subtypes - dealing with the diversity of breast
cancer: highlights of the St. Gallen International Expert Consensus
on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol.
22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eliassen AH, Tworoger SS and Hankinson SE:
Reproductive factors and family history of breast cancer in
relation to plasma prolactin levels in premenopausal and
postmenopausal women. Int J Cancer. 120:1536–1541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tworoger SS and Hankinson SE: Prolactin
and breast cancer risk. Cancer Lett. 243:160–169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuijper TM, Ruigrok-Ritstier K,
Verhoef-Post M, et al: LH receptor gene expression is essentially
absent in breast tumor tissue: implications for treatment. Mol Cell
Endocrinol. 302:58–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bodek G, Rahman NA, Zaleska M, et al: A
novel approach of targeted ablation of mammary carcinoma cells
through luteinizing hormone receptors using Hecate-CGbeta
conjugate. Breast Cancer Res Treat. 79:1–10. 2003. View Article : Google Scholar
|
|
13
|
Meduri G, Charnaux N, Loosfelt H, et al:
Luteinizing hormone/human chorionic gonadotropin receptors in
breast cancer. Cancer Res. 57:857–864. 1997.PubMed/NCBI
|
|
14
|
Meduri G, Charnaux N, Spyratos F, Hacene
K, Loosfelt H and Milgrom E: Luteinizing hormone receptor status
and clinical, pathologic, and prognostic features in patients with
breast carcinomas. Cancer. 97:1810–1816. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caffier H and Brandau H: Serum tumor
markers in metastatic breast cancer and course of disease. Cancer
Detect Prev. 6:451–457. 1983.PubMed/NCBI
|
|
16
|
Tsalacopoulos G and Bloch B: Ectopic
production of the beta subunit of human chorionic gonadotrophin by
malignant ovarian neoplasms. S Afr Med J. 62:487–488.
1982.PubMed/NCBI
|
|
17
|
Ben-Josef E, Yang SY, Ji TH, et al:
Hormone-refractory prostate cancer cells express functional
follicle-stimulating hormone receptor (FSHR). J Urol. 161:970–976.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies S, Bax CM, Chatzaki E, Chard T and
Iles RK: Regulation of endometrial cancer cell growth by
luteinizing hormone (LH) and follicle stimulating hormone (FSH). Br
J Cancer. 83:1730–1734. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen FC, Oskay-Ozcelik G, Bühling KJ, et
al: Prognostic value of serum and ascites levels of estradiol, FSH,
LH and prolactin in ovarian cancer. Anticancer Res. 29:1575–1578.
2009.PubMed/NCBI
|
|
20
|
Wayne CM, Fan HY, Cheng X and Richards JS:
Follicle-stimulating hormone induces multiple signaling cascades:
evidence that activation of Rous sarcoma oncogene, RAS, and the
epidermal growth factor receptor are critical for granulosa cell
differentiation. Mol Endocrinol. 21:1940–1957. 2007. View Article : Google Scholar
|
|
21
|
Hunzicker-Dunn M and Maizels ET: FSH
signaling pathways in immature granulosa cells that regulate target
gene expression: branching out from protein kinase A. Cell Signal.
18:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi JH, Choi KC, Auersperg N and Leung
PC: Overexpression of follicle-stimulating hormone receptor
activates oncogenic pathways in preneoplastic ovarian surface
epithelial cells. J Clin Endocrinol Metab. 89:5508–5516. 2004.
View Article : Google Scholar
|
|
23
|
Huhtaniemi I: Are gonadotrophins
tumorigenic - a critical review of clinical and experimental data.
Mol Cell Endocrinol. 329:56–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pujol P, Daures JP, Brouillet JP, et al: A
prospective prognostic study of the hormonal milieu at the time of
surgery in premenopausal breast carcinoma. Cancer. 91:1854–1861.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zreik TG, Mazloom A, Chen Y, et al:
Fertility drugs and the risk of breast cancer: a meta-analysis and
review. Breast Cancer Res Treat. 124:13–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sprengel R, Braun T, Nikolics K, Segaloff
DL and Seeburg PH: The testicular receptor for follicle stimulating
hormone: structure and functional expression of cloned cDNA. Mol
Endocrinol. 4:525–530. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kelton CA, Cheng SV, Nugent NP, et al: The
cloning of the human follicle stimulating hormone receptor and its
expression in COS-7, CHO, and Y-1 cells. Mol Cell Endocrinol.
89:141–151. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Loy T, Vandersmissen HP, Van Hiel MB,
et al: Comparative genomics of leucine-rich repeats containing G
protein-coupled receptors and their ligands. Gen Comp Endocrinol.
155:14–21. 2008.PubMed/NCBI
|
|
29
|
Hsu SY, Kudo M, Chen T, et al: The three
subfamilies of leucine-rich repeat-containing G protein-coupled
receptors (LGR): identification of LGR6 and LGR7 and the signaling
mechanism for LGR7. Mol Endocrinol. 14:1257–1271. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garde SV, Sheth AR, Joseph R, Panchal CJ,
Chinoy RF and Sheth NA: Occurrence and de novo biosynthesis of
follicle stimulating hormone (FSH) in benign and malignant
conditions of human breast. Cancer Lett. 75:1–9. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Wang B, Wang Y and Hu J: Estrogen
receptor positive operable breast cancer: does menopausal status
impact on HER2 and progesterone receptor status? Breast.
20:519–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hernández L, Nuñez-Villarl MJ,
Martínez-Arribas F, Pollán M and Schneider J: Circulating hormone
levels in breast cancer patients. Correlation with serum tumor
markers and the clinical and biological features of the tumors.
Anticancer Res. 25:451–454. 2005.PubMed/NCBI
|
|
33
|
Choi JH, Chen CL, Poon SL, Wang HS and
Leung PC: Gonadotropin-stimulated epidermal growth factor receptor
expression in human ovarian surface epithelial cells: involvement
of cyclic AMP-dependent exchange protein activated by cAMP pathway.
Endocr Relat Cancer. 16:179–188. 2009. View Article : Google Scholar
|
|
34
|
Zhang Z, Jia L, Feng Y and Zheng W:
Overexpression of follicle-stimulating hormone receptor facilitates
the development of ovarian epithelial cancer. Cancer Lett.
278:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
